共 189 条
[1]
Mitsiades CS(2011)Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma J Clin Oncol 29 1916-1923
[2]
Davies FE(2003)Novel therapeutic approaches for multiple myeloma Immunol Rev 194 164-176
[3]
Laubach JP(2001)VLA-4-dependent myeloma cell adhesion Leuk Lymphoma 41 239-245
[4]
Joshua D(1999)Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines Blood 93 1658-1667
[5]
San Miguel J(2008)ANTI-ADHESION evolves to a promising therapeutic concept in oncology Curr Med Chem 15 978-990
[6]
Anderson KC(1996)Integrin function in chronic lymphocytic leukemia Blood 87 4780-4788
[7]
Hideshima T(2003)Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia Nat Med 9 1158-1165
[8]
Richardson P(2009)Selectively targeting T- and B-cell lymphomas: A benzothiazole antagonist of alpha(4)beta(1) integrin J Med Chem 52 14-19
[9]
Anderson K(2009)Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma Oncogene 28 231-242
[10]
Sanz-Rodriguez F(2011)The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications Br J Haematol 155 438-448